(function(){var loadHandler=window['sl_{B169E353-1691-4AFC-B51D-F07AF60FC333}'];loadHandler&&loadHandler(11, '<div id="spr0_587867a3"><div id="spr1_587867a3" class="kern slide"><img id="img4_587867a3" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_587867a3" class="kern slide"><img id="img0_587867a3" src="data/img18.png" width="721.48" height="104.337" alt="" style="left:-1.48px;"/><div id="svg1_587867a3" style="left:-1.48px;top:104.237px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_587867a3" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_587867a3" src="data/img8.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_587867a3" style="left:657.715px;top:499.855px;"><img id="img2_587867a3" src="data/img9.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_587867a3" style="left:-1.454px;top:3.623px;"><div style="width:0px;"><span id="txt0_587867a3" data-width="183.695313" style="left:268.445px;top:4.901px;">Real World Data:</span></div><div style="width:0px;"><span id="txt1_587867a3" data-width="657.234375" style="left:31.54px;top:38.315px;">Treatment and LDL-C Management in Patients Diagnosed with Clinical</span></div><div style="width:0px;"><span id="txt2_587867a3" data-width="468.128906" style="left:125.795px;top:67.115px;">Atherosclerotic Cardiovascular Disease in Alberta</span></div></div><div id="spr5_587867a3" style="left:347.975px;top:158.046px;"><img id="img3_587867a3" src="data/img19.png" width="381" height="324" alt="" style="left:-0.072px;top:0.177px;"/></div><div id="spr6_587867a3" style="left:347.975px;top:118.835px;"><div style="width:0px;"><span id="txt3_587867a3" data-width="330.218750" style="left:15.25px;top:4.343px;">LDL-C levels pre-and-post PCSK9 inhibitor treatment</span></div></div><div id="spr7_587867a3" style="left:26.831px;top:180.654px;"><div style="width:0px;"><span id="txt4_587867a3" class="nokern relpos" style="left:7.2px;top:5.203px;"></span><span id="txt5_587867a3" class="relpos" data-width="259.765625" style="left:20.55px;top:4.529px;">Among  82 patients who received</span></div><div style="width:0px;"><span id="txt6_587867a3" data-width="259.287109" style="left:29.7px;top:28.529px;">PCSK9 inhibitors, n = 41 had pre-</span></div><div style="width:0px;"><span id="txt7_587867a3" data-width="245.087891" style="left:29.7px;top:52.529px;">and post-treatment LDL-C tests</span></div></div><div id="svg4_587867a3" style="left:24.904px;top:295.802px;"><svg width="303" height="80" viewBox="0 0 303 80"><path fill="#d2eefa" d="M0,0 h302.214 v79.973 h-302.214 Z"/></svg></div><div id="spr8_587867a3" style="left:24.904px;top:295.802px;"><div style="width:0px;"><span id="txt8_587867a3" class="nokern relpos" style="left:7.2px;top:5.203px;"></span><span id="txt9_587867a3" class="relpos" data-width="235.117188" style="left:20.55px;top:4.529px;">In these patients, mean LDL-C</span></div><div style="width:0px;"><span id="txt10_587867a3" data-width="255.283203" style="left:29.7px;top:28.529px;">decreased from 2.5 ± 1.3 mmol/L</span></div><div style="width:0px;"><span id="txt11_587867a3" data-width="148.623047" style="left:29.7px;top:52.529px;">to 1.3 ± 1.2 mmol/L</span></div></div><div id="spr9_587867a3" style="left:500.867px;top:180.654px;"><div style="width:0px;"><span id="txt12_587867a3" class="nokern" data-width="160.172852" style="left:8.078px;top:4.371px;">Mean (SD) days between tests:</span></div><div style="width:0px;"><span id="txt13_587867a3" class="nokern relpos" data-width="25.539063" style="left:42.077px;top:21.05px;">48.5 </span><span id="txt14_587867a3" class="nokern relpos" style="left:42.072px;top:22.916px;">±</span><span id="txt15_587867a3" class="nokern relpos" data-width="54.899414" style="left:42.067px;top:21.05px;"> 45.5 days</span></div></div><div id="spr10_587867a3" style="left:367.581px;top:290.329px;"><div style="width:0px;"><span id="txt16_587867a3" class="nokern relpos" data-width="19.154297" style="left:62.14px;top:4.25px;">2.5 </span><span id="txt17_587867a3" class="nokern relpos" data-width="26.837891" style="left:62.135px;top:4.25px;">± 1.3</span></div></div><div id="spr11_587867a3" style="left:518.316px;top:351.541px;"><div style="width:0px;"><span id="txt18_587867a3" class="nokern relpos" data-width="19.154297" style="left:62.14px;top:4.25px;">1.3 </span><span id="txt19_587867a3" class="nokern relpos" data-width="26.837891" style="left:62.135px;top:4.25px;">± 1.2</span></div></div><div id="spr12_587867a3" style="left:330.972px;top:159.991px;"><div style="width:0px;"><span id="txt20_587867a3" data-width="114.809570" style="left:7.85px;top:198.027px;">LDL-C level (mmol/L)</span></div></div><div id="spr13_587867a3" style="left:14.754px;top:457.65px;"><div style="width:0px;"><span id="txt21_587867a3" class="nokern" data-width="104.795410" style="left:7.2px;top:4.206px;">Supplementary Figure S1.</span></div><div style="width:0px;"><span id="txt22_587867a3" class="nokern" data-width="269.236816" style="left:7.2px;top:17.406px;">Mean (±SD) LDL-C levels pre- and post- PSCK9 inhibitor treatment</span></div></div><div id="spr14_587867a3" style="left:4.43px;top:506.2px;"><div style="width:0px;"><span id="txt23_587867a3" class="nokern" data-width="146.478516" style="left:7.2px;top:4.096px;">Chen et al. Can J Cardiol. 2019. 35:884-891.</span></div></div></div></div>');})();